Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 30, 2012
Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagyYan Zang, Sufi M Thomas, Elena T Chan, et al.
Autophagy|September 22, 2012
The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4Yan Zang, Sufi M Thomas, Elena T Chan, et al.
Comparative Biochemistry and Physiology. Part A, Molecular & Integrative Physiology|May 3, 2003
Environmental endocrine disrupters dysregulate estrogen metabolism and Ca2+ homeostasis in fish and mammals via receptor-independent mechanismsChristopher J Kirk, Laura Bottomley, Nicholas Minican, et al.
Biochemical Pharmacology|February 21, 2014
Anti-leukemic activity and mechanisms underlying resistance to the novel immunoproteasome inhibitor PR-924Denise Niewerth, Johan van Meerloo, Gerrit Jansen, et al.
Frontiers in Immunology|March 27, 2023
Zetomipzomib (KZR-616) attenuates lupus in mice via modulation of innate and adaptive immune responsesTony Muchamuel, R Andrea Fan, Janet L Anderl, et al.
Arthritis and Rheumatism|September 10, 2011
Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cellsH Travis Ichikawa, Thomas Conley, Tony Muchamuel, et al.
Chemistry & Biology|November 13, 2012
Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicityHao Li, Elizabeth L Ponder, Martijn Verdoes, et al.
Brain : a Journal of Neurology|April 23, 2013
Reactive glia show increased immunoproteasome activity in Alzheimer's diseaseMarie Orre, Willem Kamphuis, Stephanie Dooves, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 3, 2011
Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse eventsShirin Arastu-Kapur, Janet L Anderl, Marianne Kraus, et al.
EMBO Reports|October 4, 2018
Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunityMichael Basler, Michelle M Lindstrom, Jacob J LaStant, et al.
Pageof 6